CYP51/HDAC-IN-1

• UNSPSC Description:

  CYP51/HDAC-IN-1 is a potent, orally active CYP51/HDAC dual inhibitor. CYP51/HDAC-IN-1 inhibits important virulence factors and down-regulated resistance-associated genes. CYP51/HDAC-IN-1 exhibits potent therapeutic effects for both tropical candidiasis and cryptococcal meningitis[1].

• Target Antigen:

  Cytochrome P450; Fungal; HDAC

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Cell Cycle/DNA Damage;Epigenetics;Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cyp51-hdac-in-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(CCCCCCCOC1=CC=C(CN2CCN(CC(C3=CC=C(C=C3F)F)(CN4N=CN=C4)O)CC2)C=C1)NO

• Molecular Weight:

  586.67

• References & Citations:

  [1]Zhu T, et al. Lanosterol 14α-demethylase (CYP51)/histone deacetylase (HDAC) dual inhibitors for treatment of Candida tropicalis and Cryptococcus neoformans infections. Eur J Med Chem. 2021. 221:113524.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2502095-64-7